R. Vimercati
About
In The Last Decade
R. Vimercati
23 papers receiving 415 citations
Peers
Comparison fields: 5 of 45
- Hematology 273
- Genetics 192
- Oncology 145
- Pathology and Forensic Medicine 119
- Immunology 66
Countries citing papers authored by R. Vimercati
This map shows the geographic impact of R. Vimercati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Vimercati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Vimercati more than expected).
Fields of papers citing papers by R. Vimercati
This network shows the impact of papers produced by R. Vimercati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Vimercati. The network helps show where R. Vimercati may publish in the future.
Co-authorship network of co-authors of R. Vimercati
This figure shows the co-authorship network connecting the top 25 collaborators of R. Vimercati. A scholar is included among the top collaborators of R. Vimercati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Vimercati. R. Vimercati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 7 | |
| 4 | 0 | |
| 5 | Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. | 24 |
| 6 | Fludarabine in combination: An effective therapy for relapsed or refractory low-grade non-Hodgkin's lymphoma (LGL): A multicentre experience | 1 |
| 7 | 7 | |
| 8 | 22 | |
| 9 | 10 | |
| 10 | 29 | |
| 11 | High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. | 19 |
| 12 | Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. | 22 |
| 13 | Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. | 29 |
| 14 | Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. | 91 |
| 15 | 3 | |
| 16 | 3 | |
| 17 | 52 | |
| 18 | VM-26 and cytarabine combination chemotherapy in refractory or relapsed adult acute lymphoblastic leukemia. | 1 |
| 19 | Lack of in vitro colony (CFUC) formation and myelosuppressive activity in patients with severe aplastic anemia after autologous hematologic reconstitution. | 32 |
| 20 | Major ABO incompatible bone marrow transplantation. | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.